Baxter International Inc. and its executives allegedly misled shareholders about systemic safety issues with its new IV fluid pump, which eventually led the company to halt sales, causing a stock drop ...

The company, which has not received any complaints related to the issue, previously discontinued the devices affected by the expanded recall. The company wrote to customers on July 8 to flag potential ...

The Alaris infusion system [Image courtesy of BD] BD (NYSE:BDX) announced a voluntary recall related to certain Alaris and Alaris infusion pump modules. Affected Alaris products may have been serviced ...

BD (NYSE: BDX) + is dealing with another recall related to its Alaris infusion pump system. Our sister site, Drug Delivery Business News, reports that the medtech giant announced a voluntary recall ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued a voluntary recall related to certain Alaris™ and BD Alaris™ Pump Modules that may have been ...

Nearly 70% of patients with acute upper gastrointestinal (GI) bleeding and low-risk or no peptic ulcer disease received intravenous (IV) proton pump inhibitors (PPIs) inappropriately, leading to ...

The global MRI-Compatible IV Infusion Pump Systems Market is estimated to be valued at USD 322.5 million in 2025 and is projected to reach USD 742.9 million by 2035, registering a compound annual ...

Nasal spray flat icon. Sore throat medicine bottle isolated on... IV bag icons set in black and colored versions IV bag icons set in black and colored versions iv pump stock illustrations IV bag icons ...

Becton Dickinson (BD) medical device company will pay $175 million for “repeatedly” misleading investors about its Alaris infusion pump, a product the company knew was flawed and was sold without the ...

The U.S. Securities and Exchange Commission revealed on Monday that it has reached a settlement with Becton Dickinson and Co. regarding allegations of investor misinformation about the risks related ...